Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of HW241045 in Healthy Participants
NCT07593690Phase 1Not yet recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HW241045 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute. Primary endpoint: Treatment Emergent Adverse Events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HW241045
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07593690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593690.